Type 1 type 2 immunity in infectious diseases

被引:640
作者
Spellberg, B
Edwards, JE
机构
[1] Univ Calif Los Angeles, Harbor Med Ctr, Dept Internal Med, Torrance, CA 90509 USA
[2] Univ Calif Los Angeles, Harbor Med Ctr, Div Infect Dis, Torrance, CA 90509 USA
关键词
D O I
10.1086/317537
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-gamma, and lymphotoxin-alpha and stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. Type 1 and type 2 immunity are not strictly synonymous with cell-mediated and humoral immunity, because Th1 cells also stimulate moderate levels of antibody production, whereas Th2 cells actively suppress phagocytosis. For most infections, save those caused by large eukaryotic pathogens, type 1 immunity is protective, whereas type 2 responses assist with the resolution of cell-mediated inflammation. Severe systemic stress, immunosuppression, or overwhelming microbial inoculation causes the immune system to mount a type 2 response to an infection normally controlled by type 1 immunity. In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection.
引用
收藏
页码:76 / 102
页数:27
相关论文
共 427 条
[1]   Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen [J].
Abuodeh, RO ;
Shubitz, LF ;
Siegel, E ;
Snyder, S ;
Peng, T ;
Orsborn, KI ;
Brummer, E ;
Stevens, DA ;
Galgiani, JN .
INFECTION AND IMMUNITY, 1999, 67 (06) :2935-2940
[2]   Haemophilus influenzae and Streptococcus pyogenes group A challenge induce a Th1 type of cytokine response in cells obtained from tonsillar hypertrophy and recurrent tonsillitis [J].
Ågren, K ;
Brauner, A ;
Andersson, J .
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 1998, 60 (01) :35-41
[3]  
Alleva DG, 1998, J IMMUNOL, V161, P6878
[4]  
Almawi WY, 1996, J IMMUNOL, V157, P5231
[5]  
Aloisi F, 1999, EUR J IMMUNOL, V29, P2705, DOI 10.1002/(SICI)1521-4141(199909)29:09<2705::AID-IMMU2705>3.0.CO
[6]  
2-1
[7]   Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection [J].
Altare, F ;
Lammas, D ;
Revy, P ;
Jouanguy, E ;
Döffinger, R ;
Lamhamedi, S ;
Drysdale, P ;
Scheel-Toellner, D ;
Girdlestone, J ;
Darbyshire, P ;
Wadhwa, M ;
Dockrell, H ;
Salmon, M ;
Fischer, A ;
Durandy, A ;
Casanova, JL ;
Kumararatne, DS .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) :2035-2040
[8]   Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency [J].
Altare, F ;
Durandy, A ;
Lammas, D ;
Emile, JF ;
Lamhamedi, S ;
Le Deist, F ;
Drysdale, P ;
Jouanguy, E ;
Döffinger, R ;
Bernaudin, F ;
Jeppsson, O ;
Gollob, JA ;
Meinl, E ;
Segal, AW ;
Fischer, A ;
Kumararatne, D ;
Casanova, JL .
SCIENCE, 1998, 280 (5368) :1432-1435
[9]   Tumor necrosis factor α is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection [J].
Artis, D ;
Humphreys, NE ;
Bancroft, AJ ;
Rothwell, NJ ;
Potten, CS ;
Grencis, RK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) :953-962
[10]   Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial [J].
Asadullah, K ;
Döcke, WD ;
Ebeling, M ;
Friedrich, M ;
Belbe, G ;
Audring, H ;
Volk, HD ;
Sterry, W .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :187-192